Skip to content

Invitation to presentation of BioArctic’s Full Year Report for the period January – December 2019 on February 6 at 9.30 a.m. CET

Non Regulatory

Stockholm, Sweden, January 28, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report for the period January – December 2019 on Thursday, February 6, 2020, at 08:00 a.m. CET.

BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media on February 6, at 09:30 – 10:30 a.m. CET.

Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment on the Full Year Report for the period January – December 2019 followed by a Q&A-session.

To attend, please dial-in at one of the numbers below, from:
Sweden: + 46 8 505 583 55
Denmark: + 45 354 455 77
Germany: + 49 691 380 3452
The Netherlands: + 31 207 095 189
Norway: + 47 235 002 43
Switzerland: + 41 225 805 976
UK: + 44 333 300 9265
US: + 1 833 823 0589


The webcast will afterwards also be available on demand at BioArctic’s corporate website, Investors, Financial presentations.

For more information, please contact:
Jan Mattsson, CFO
Telephone: + 46 70 352 27 72

This information was submitted for publication at 08:30 a.m. CET on January 28, 2020.

About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit